jueves, 5 de junio de 2025
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study +++
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00023-2/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsenc=p2ANqtz-_6t3ir95e_x68PiHFJL_q1x4LVVoHnsngOP6IrDbKTlMAZ14VDgrJJwpb2pC5aH6ZM5H0dW0BBn0Hx8XbE9swl7ATl_g&_hsmi=364866195&utm_content=364799189&utm_source=hs_email
Jun 2025
Volume 7Number 6e377-e450
Editorial
e377
IgG4-related disease: the future is promising
The Lancet Rheumatology
https://www.thelancet.com/journals/lanrhe/issue/vol7no6/PIIS2665-9913(25)X0006-0
Reasoning large language models in rheumatology: a call for responsible action
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00101-8/abstract?utm_campaign=update-lanrhe&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanrhe&_hsenc=p2ANqtz-86mgV5tPGMRksqkxqlsV5nkI5EuhkBmbmOq1BOD9Mwz80DtgWxZJ3vU3hyR8J1fO5Wfq4BqiGkBgWd9EnOdeUU--Rnsg&_hsmi=364866195&utm_content=364799189&utm_source=hs_email
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario